|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2000029148 |
|
最近更新日期: Date of Last Refreshed on: |
2020-01-17 00:38:12 |
|
注册时间: Date of Registration: |
2020-01-16 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
体外激活卵子后自体卵巢组织原位移植的辅助生殖技术临床研究 |
|
Public title: |
Clinical study for assisted reproductive technology in orthotopic transplantation of autogenous ovarian tissue after activation of egg in vitro |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
体外激活卵子后自体卵巢组织原位移植的辅助生殖技术临床研究 |
|
Scientific title: |
Clinical study for assisted reproductive technology in orthotopic transplantation of autogenous ovarian tissue after activation of egg in vitro |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
洪志丹 |
研究负责人: |
马玲 |
|
Applicant: |
Hong Zhidan |
Study leader: |
Ma Ling |
|
申请注册联系人电话: Applicant telephone: |
+86 13476191768 |
研究负责人电话: Study leader's telephone: |
+86 18502729279 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
95298450@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
810323923@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
武汉市武昌区东湖路169号 |
研究负责人通讯地址: |
武汉市武昌区东湖路169号 |
|
Applicant address: |
169 Donghu Road, Wuchang District, Wuhan, Hubei, China |
Study leader's address: |
169 Donghu Road, Wuchang District, Wuhan, Hubei, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
武汉大学中南医院 |
||
|
Applicant's institution: |
Zhongnan Hospital of Wuhan University |
||
|
研究负责人所在单位: |
武汉大学中南医院 |
||
|
Affiliation of the Leader: |
Zhongnan Hospital of Wuhan University |
||
|
是否获伦理委员会批准: |
否/No |
||
|
Approved by ethic committee: |
No |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦理委员会批件附件: Approved file of Ethical Committee: |
||
|
批准本研究的伦理委员会名称: |
|
||
|
Name of the ethic committee: |
|
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2013-08-26 00:00:00 |
||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
武汉大学中南医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Zhongnan Hospital of Wuhan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
武汉大学中南医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
169 Donghu Road, Wuchang District, Wuhan, Hubei, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
医院支持 |
||||||||||||||||||||||
|
Source(s) of funding: |
Hospital project |
||||||||||||||||||||||
|
Target disease: |
DOR(diminished ovarian reserve) |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
主要研究目的:研究腹腔镜下卵巢部分组织分离并体外给与激活剂激活后再次原位移植回卵巢是否可以导致卵子的激活,诱发POF患者卵子的重新生长发育和成熟,最终达到妊娠,分娩。 次要研究目的: 1、研究激活后患者激素水平的变化。 2、研究激活后促排卵时间及促排卵方案 3、研究激活后分娩婴儿安全性问题。 |
||||||||||||||||||||||
|
Objectives of Study: |
The main purpose of this study is to investigate whether the ovarian tissue can be activated by orthotopic ovarian transplantation after laparoscopic ovarian tissue separation and activator activation in vitro, and to induce the growth and maturation of POF patients' eggs, and finally achieve pregnancy and delivery. Secondary research objectives: 1. To study the changes of hormone levels in patients after activation; 2. Study on the time and plan of ovulation induction after activation; 3. To study the safety of delivery infants after activation. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1、年龄20-40岁,曾有月经史; |
||||||||||||||||||||||
|
Inclusion criteria |
1. Aged 20-40 years old, had menstrual history; |
||||||||||||||||||||||
|
排除标准: |
1、年龄>41岁; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Severe hypertension, diabetes, heart disease and other organic diseases can not tolerate surgery and pregnancy; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-01-01 00:00:00至 To 2022-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2020-01-01 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
自身前后对照 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2023.06 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
2023.06 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |